Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Tumor stromal phenotypes define VEGF sensitivity--response.

Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST.

Clin Cancer Res. 2014 Oct 1;20(19):5141. doi: 10.1158/1078-0432.CCR-14-0681. No abstract available.

2.

Tumor stromal phenotypes define VEGF sensitivity--letter.

Van den Eynden GG, Bird NC, Dirix LY, Eefsen RL, Gao ZH, Høyer-Hansen G, Illemann M, Majeed AW, Metrakos P, Reynolds AR, Vainer B, van Dam PJ, Van Laere SJ, Vermeulen PB, Vidal-Vanaclocha F, Brodt P; Liver Metastasis Research Network.

Clin Cancer Res. 2014 Oct 1;20(19):5140. doi: 10.1158/1078-0432.CCR-14-0158. No abstract available.

3.

The context of blood vessels and response to VEGF-targeted therapy.

Rini BI.

Clin Cancer Res. 2013 Dec 15;19(24):6647-9. doi: 10.1158/1078-0432.CCR-13-2479. Epub 2013 Oct 28.

4.

Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.

Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST.

Clin Cancer Res. 2013 Dec 15;19(24):6943-56. doi: 10.1158/1078-0432.CCR-13-1637. Epub 2013 Sep 12.

5.

Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer.

Tayama M, Furuhata T, Inafuku Y, Okita K, Nishidate T, Mizuguchi T, Kimura Y, Hirata K.

World J Gastroenterol. 2011 Nov 28;17(44):4867-74. doi: 10.3748/wjg.v17.i44.4867.

6.

VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.

Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12.

7.

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV.

J Clin Invest. 2011 Apr;121(4):1313-28. doi: 10.1172/JCI42405. Epub 2011 Mar 23.

8.

Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA.

Mol Med. 2011;17(7-8):619-27. doi: 10.2119/molmed.2010.00210. Epub 2011 Apr 14.

9.

VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization.

O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, Neilson EG, Zeisberg M, Kalluri R.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16002-7. doi: 10.1073/pnas.1109493108. Epub 2011 Sep 12.

10.

Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells.

Chen W, Tang T, Eastham-Anderson J, Dunlap D, Alicke B, Nannini M, Gould S, Yauch R, Modrusan Z, DuPree KJ, Darbonne WC, Plowman G, de Sauvage FJ, Callahan CA.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9589-94. doi: 10.1073/pnas.1017945108. Epub 2011 May 19.

11.

Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.

Li Y, Liang XY, Yue YQ, Sheng L, Liu JK, Wang ZY, Chen G.

Tumour Biol. 2016 May;37(5):6297-306. doi: 10.1007/s13277-015-4493-9. Epub 2015 Nov 30.

PMID:
26619847
12.

Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis.

Claffey KP, Abrams K, Shih SC, Brown LF, Mullen A, Keough M.

Lab Invest. 2001 Jan;81(1):61-75.

PMID:
11204275
13.

Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis.

Eng L, Azad AK, Habbous S, Pang V, Xu W, Maitland-van der Zee AH, Savas S, Mackay HJ, Amir E, Liu G.

Clin Cancer Res. 2012 Sep 1;18(17):4526-37. Epub 2012 Jun 25.

14.

Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.

Solberg TD, Nearman J, Mullins J, Li S, Baranowska-Kortylewicz J.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):918-26. doi: 10.1016/j.ijrobp.2008.06.1925.

15.

Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells.

Ritter E, Perry A, Yu J, Wang T, Tang L, Bieberich E.

Ann Surg. 2008 Feb;247(2):310-4. doi: 10.1097/SLA.0b013e31816401d5.

PMID:
18216538
16.

MEK/ERK signaling is involved in the role of VEGF and IGF1 in cardiomyocyte differentiation of mouse adipose tissue-derived stromal cells.

Wang C, Liu W, Zhang X, Wang Y, Liu H, Li H.

Int J Cardiol. 2017 Feb 1;228:427-434. doi: 10.1016/j.ijcard.2016.11.199. Epub 2016 Nov 9.

PMID:
27870972
17.

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R.

Invest New Drugs. 2015 Feb;33(1):215-24. doi: 10.1007/s10637-014-0176-4. Epub 2014 Nov 4.

18.

Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.

Hirashima Y, Yamada Y, Matsubara J, Takahari D, Okita N, Takashima A, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H, Shimoda T.

Cancer Sci. 2009 Feb;100(2):310-5. doi: 10.1111/j.1349-7006.2008.01020.x.

19.
20.

Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases.

Tse GM, Lui PC, Lee CS, Kung FY, Scolyer RA, Law BK, Lau TS, Karim R, Putti TC.

Hum Pathol. 2004 Sep;35(9):1053-7.

PMID:
15343505

Supplemental Content

Support Center